Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Neuroactive Steroids in Acute Ischemic Stroke (Cortisol)

7 août 2017 mis à jour par: Sebastian Casas, Hospital Militar Central, Argentina

Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke

Acute ischemic stroke (AIS) represents an economical challenge for health systems all over the globe. Despite increasing knowledge of the pathophysiology of AIS, there is no satisfactory treatment to revert the resulting brain damage. Changes of neuroactive steroids have been found in different neurological diseases. In this regard, the investigators have previously demonstrated that old patients with AIS show changes of plasma cortisol and estradiol concentrations, in that increased steroid levels are associated with a deterioration of neurological status and a worse cognitive decline. The present study assessed in patients with AIS if changes of behavior, brain-derived neurotrophic factor (BDNF) and nitrites (NO-2) (nitric oxide soluble metabolite) bear a relationship with the degree of hypercortisolism. To this purpose, the investigators recruited patients hospitalized at the Central Military Hospital emergency room within the first 24 hours of AIS. Subjects were divided into two groups, each one composed of 40 control subjects and 40 AIS patients, including men and women. The neurological condition was assessed using the NIHSS and the cognitive status with the Montreal Cognitive Assessment (MoCA test). The emotional status was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS), whereas the Modified Rankin Scale (MRS) was used to determine the functional condition. BDNF and NO-2 plasma levels were measured by ELISA and the Griess reaction method, respectively.

Aperçu de l'étude

Statut

Complété

Intervention / Traitement

Description détaillée

Acute Ischemic Stroke (AIS) is one of the main causes of functional deterioration all over the world. Thus, 26% of patients older than 65 years still show limitations of daily activities 6 months after AIS, and 46% of these patients present cognitive deficiency of variable severity. AIS impose a burden on the way of living of patients and their families' in which depression emerges as a frequent neuropsychiatric disorder after the ischemic event. However, the occurrence of depression and other functional abnormalities on the first day following AIS is largely unknown. Neuroactive steroids have the capability to modulate in a positive or negative way the function of the nervous system. Changes in neuroactive steroid concentrations in plasma and nervous system have been described in degenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis), autoimmune diseases (multiple sclerosis), epilepsy, and psychiatric disorders (depression and schizophrenia). In vulnerable regions such as the hippocampus and prefrontal cortex, high cortisol exposure damages the pyramidal neurons, decreases neurogenesis and impairs memory and learning. In a previous report, the investigators have demonstrated that old patients with AIS show changes in the plasma levels of cortisol and estradiol, which associate with low cognition, worse neurological status, and poor functional performance. The present report investigated changes of cortisol, brain-derived neurotrophic factor (BDNF) and nitrites (NO-2, nitric oxide soluble metabolites) after AIS. BDNF is a neurotrophin classically associated with learning and memory and negatively modulated by glucocorticoids, old age, and neurodegenerative diseases. In plasma, platelets are the major source of peripheral BDNF and levels of this neurotrophin are decreased in Alzheimer´s disease and depression. These disorders also show hypercortisolism and changes of cortisol dynamics suggesting that steroids, neurotrophins, and behavioral deficits may be functionally related. Regarding nitrites, cortisol treatment of human subjects significantly reduced plasma nitrate/nitrite concentrations. Therefore, considering that opposite changes occur in cortisol vs. BDNF and nitrites, the investigators aimed to determine in acute AIS patients (a) changes in plasma cortisol; (b) development of clinical, behavioral and functional deficits; (c) changes in plasma BDNF and nitrites, which may predict a neurotoxic effect of the excess cortisol in the ischemic nervous system.

Type d'étude

Observationnel

Inscription (Réel)

40

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans à 90 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

The subjects were between 60 and 90 years old, and were recruited randomly and distributed in two experimental groups: 1) a control group composed of subjects without physical or psychiatric disease, 2) an AIS group composed of subjects within the first 24 hours of the neurovascular event. The individuals were distributed in such a way that each experimental group contained 10 men and 10 women. Table 1 show the inclusion and exclusion criteria used for the AIS group.

La description

Inclusion Criteria:

  • Age between 60 and 90 years.
  • Agreeing to participate in the study.
  • Acute Ischemic Stroke of anterior vascular territory and/or posterior vascular territory whithin 24 hours of onset.
  • Nine or more points in the Glasgow Coma Scale.
  • Female patients in menopause.
  • Patients without cognitive impairment before AIS according to family reference.
  • Acceptance of the next of kin proxy in case the participant has sensory impairment.

Exclusion Criteria:

  • Age <60 or > 90 years.
  • Hemorrhagic Stroke.
  • Transient ischemic attack (TIA).
  • Acute Ischemic Stroke after 24 hours of onset.
  • Hormonal replacement therapy.
  • Immunosuppressive therapy in the last month before AIS (example corticosteroids).
  • Acute infection (Example, pneumonia, urinary tract infection).
  • Diagnosis of oncologic disease in the last month before AIS.
  • Diagnosis of endocrinologic disease in the last month before AIS.
  • Acute or long-term psychiatric illness.
  • No agreement to participate in the study.
  • Eight or less points in the Glasgow Coma Scale.
  • Female patients with menstrual cycle or in the perimenopause.
  • Patients with kidney or hepatic illness.
  • Patients with cognitive impairment before AIS.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cas-témoins
  • Perspectives temporelles: Éventuel

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Control group
A control group composed of subjects without physical or psychiatric disease.
We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
Autres noms:
  • Plasma cortisol levels quantification
  • Plasma nitrites levels quantification
  • Plasma Brain Derived Neurotrophic Factor quantification
Acute Ischemic Stroke group
An AIS group composed of subjects within the first 24 hours of the neurovascular event.
We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
Autres noms:
  • Plasma cortisol levels quantification
  • Plasma nitrites levels quantification
  • Plasma Brain Derived Neurotrophic Factor quantification

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Neurological déficit
Délai: Into 24 hours of Acute Ischemic Stroke
The neurological state during AIS was quantified by the National Institute of Health stroke scale at the time of hospitalization (NIHSS,available at http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf
Into 24 hours of Acute Ischemic Stroke

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Cognition
Délai: Into 24 hours of Acute Ischemic Stroke
The cognitive test used was the Montreal Cognitive Assessment (MoCA test).
Into 24 hours of Acute Ischemic Stroke
Emotional state
Délai: Into 24 hours of Acute Ischemic Stroke
Patients with AIS were evaluated on the Montgomery-Asberg depression scale (MADRS)
Into 24 hours of Acute Ischemic Stroke
Functional dependency of daily life activities
Délai: Into 24 hours of Acute Ischemic Stroke
The functional state of the AIS patients was assessed by the modified Rankin scale at the time of entering the admission floor.
Into 24 hours of Acute Ischemic Stroke
Cortisol
Délai: Into 24 hours of Acute Ischemic Stroke
Plasma cortisol concentration was determined by chemiluminescent microparticle immunoassay (CMIA), using Team Architect i1000, Abbott Laboratories, Middletown, USA.
Into 24 hours of Acute Ischemic Stroke
Quantification of nitrites concentration (NO-2)
Délai: Into 24 hours of Acute Ischemic Stroke
Levels of NO-2, nitric oxide soluble metabolite (ON.) in water, were measured spectrophotometrically at 543 nm absorbance by the Griess reactio
Into 24 hours of Acute Ischemic Stroke
BDNF quantification in plasma
Délai: Into 24 hours of Acute Ischemic Stroke
Plasma BDNF concentration was measured by enzyme-linked immunosorbent assay (ELISA)
Into 24 hours of Acute Ischemic Stroke

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Sebastian M Casas, Ph.D., MD., Hospital Militar Central Cir My ¨Dr. Cosme Argerich¨

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 avril 2016

Achèvement primaire (Réel)

1 décembre 2016

Achèvement de l'étude (Réel)

1 décembre 2016

Dates d'inscription aux études

Première soumission

2 août 2017

Première soumission répondant aux critères de contrôle qualité

7 août 2017

Première publication (Réel)

8 août 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 août 2017

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 août 2017

Dernière vérification

1 août 2017

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

Non

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Behavioral tests

S'abonner